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Background: Some recent experimental data suggest a possible role of LINGO-1 in the pathogenesis of multiple
sclerosis (MS). In an attempt to identify genetic biomarkers related to MS susceptibility, we genotyped two
common SNPs in the LINGO1 gene which have been associated to other neurological conditions, in patients with
MS and in healthy subjects. These SNPs are linked to several SNPs within the LINGO1 gene, especially in individuals
of Oriental or Caucasian descent.
Methods: We analyzed the allelic and genotype frequency of two LINGO1 variants (rs9652490 and rs11856808) in
293 patients with MS and 318 healthy controls, using KASPar assays.
Results: LINGO1 rs9652490 and rs11856808 allelic and genotype frequencies did not differ significantly between MS
patients and controls. The minor allele frequencies for rs9652490 were 0.171 (95% CI = 0.140-0.201) and 0.167 (95%
CI = 0.138-0.196 for cases and controls respectively (p = 0.853). For rs11856808 the minor allele frequencies were
0.317 (95% CI = 0.280-0.355) and 0.310 (95% CI = 0.274-0.346) for cases and controls, respectively (p = 0.773). Allele
and genotype frequencies were unrelated with the age of onset of MS, gender, and clinical course of MS. In
addition, haplotype analyses did not reveal any putative risk related to haplotypes.
Conclusions: These results suggest that LINGO1 rs9652490 and rs11856808 polymorphisms are not related with risk
for MS. This study adds to other published evidence indicating that, to date, the LINGO1 SNPs studied here could
be useful risk biomarkers of developing essential tremor, but not other movement disorders.
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Multiple sclerosis (MS) is a chronic inflammatory de-
myelinating disorder with axonal degeneration affecting
the Central Nervous system, which shows three major
evolutive phenotypes: relapsing-remitting, primary pro-
gressive and secondary progressive. The etiology of MS
is unknown, but it is probably multifactorial, with an
interplay of genetic, ethnic, geographical and environ-
mental factors (infectious or chemical) [1-5]. It has
been proposed that MS is an autoimmune disorder* Correspondence: elenag@unex.es
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distribution, and reproduction in any mediumwith susceptibility influenced, if not determined, by a
relatively small number of genes [1]. Findings from
studies on seasonality in MS patients’ birth, disease
onset and exacerbations, as well as apparent temporal
trends in incidence and gender ratio support an influ-
ential effect of viruses, metabolic and lifestyle factors
on MS risk. Epstein-Barr virus, vitamin D status, and
smoking are factors that may explain such epidemio-
logical patterns [4].
A haplotype within the major histocompatibility region
is the major risk factor for MS. But despite clear evi-
dence for a genetic component additional risk, specific
gene variants were not identified until the recent advententral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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11 GWAS have been conducted on MS, and, together
with follow-up studies, these GWAS have confirmed 16
loci with genome-wide significance [6,7]. Many of these
common risk variants are located at, or near to, genes
with central immunological functions (such as interleu-
kin 2 and 7 receptors, CD58, CD6, CD40, TNFRSF1A
and others) and the majority are associated with other
autoimmune diseases [6,7]. A further report of the Inter-
national Multiple Sclerosis Genetics Consortium identi-
fied at least 50 loci related with the risk for MS [8].
Although the underlying molecular mechanisms for
the axonal degeneration are unknown, the degree of in-
flammatory demyelination correlates with the extent of
axonal damage. This suggests an involvement of the
proinflammatory mediators in inducing axonal degener-
ation [9]. However, the alternative possibility that axonal
regeneration should be severely impaired in MS lesions
could be suggested, since an accumulation of glial scar
and neurite growth inhibitors provide a non-permissive
environment for re-growth of damaged axons [10].
LINGO1 (leucine rich repeat and Ig domain containing
Nogo receptor interacting protein-1) has a possible role in
the pathogenesis of MS. LINGO1 is a transmembrane
protein expressed in neural cells which inhibits the
differentiation of oligodendrocyte precursor cells into
mature oligodendrocytes, as well as myelination and
remyelination [11,12]. LINGO1 comprises 12 leucine rich
repeats followed by an immunoglobulin (Ig) domain and a
short cytoplasmic tail. It is encoded by the LINGO1 gene
(OMIM 609791, Gene Identity 84894) located in the
chromosome 15q24.3 [13,14]. In neurons, LINGO1 simul-
taneously interacts with the Nogo-66 receptor (NgR) and
p75NTR or TROY to form a receptor complex that binds
the structurally diverse associated glycoprotein and oligo-
dendrocyte myelin glycoprotein, resulting in the restric-
tion of axonal elongation via activation of the small
GTPase RhoA [14-16]. Two LINGO1 variants designated
as rs9652490 and rs11856808 have been claimed to be
associated in case–control GWAS with other neurolo-
gical conditions such as essential tremor [17,18] and
Parkinson’s disease [18,19]. Further studies confirmed the
association with essential tremor, but discarded a major
association with Parkinson’s disease [20-24]. These single
nucleotide polymorphisms (SNPs) are, according to
HapMap, tag-SNPs for the following SNPs located within
the LINGO1 gene: rs907400, rs8029432, rs1877294,
rs7165679, rs9920101 and rs9920127, as well as nine
additional SNPs in the 3’ flanking region of the gene.
Figure 1 shows that the linkage between the two SNPs an-
alyzed in this study and the six SNPs located within the
gene differ, depending on ethnicity.
In an attempt to identify additional factors involved in
MS susceptibility, we genotyped the SNPs rs9652490and rs11856808 in the LINGO1 gene, in patients with
MS and in healthy subjects. Although LINGO1 polymor-
phisms were not significantly associated with the risk and
hence are not mentioned among the possible susceptibility
genes in GWAS studies, the possible role of LINGO1 in
the pathogenesis of MS suggests that the LINGO1 gene
should be a candidate gene for modifying MS risk.
Methods
Patients and controls
We recruited 293 unrelated Caucasian Spanish patients
who fulfilled McDonald’s criteria for definite MS [25],
with no other previous neurological diseases. Recruiting
sources were the following: the “Multiple Sclerosis Asso-
ciation of Madrid”; n = 165 cases), the Health Areas of
the Hospital La-Mancha-Centro (Alcázar de San Juan,
Ciudad Real; n = 65 cases), and University Hospitals
“Doce de Octubre” (Madrid, n = 32 cases), and “Príncipe
de Asturias” (Alcalá de Henares, Madrid; n = 31 cases).
The control group was composed of 318 healthy unre-
lated Caucasian Spanish individuals gender and age-
matched with the patients (97 men, 221 women; mean
age 43.76 ± 12.4 years). These patients participated in
previous genetic studies [26-28]. The control individuals
were students or professors from the University of
Extremadura, Badajoz, Spain (n = 150), and the healthy
spouses of patients with neurological disorders who
came from different regions of Spain to the Department
of Neurology, Clínica Universitaria de Navarra, University
of Navarra School of Medicine, Pamplona, Spain (n = 168).
All the participants were included in the study after giving
written informed consent. Table 1 summarizes the charac-
teristics of the individuals included in the study. The proto-
col was approved by the Ethics Committees of the
University Hospitals “Príncipe de Asturias” and “Infanta
Cristina” (Badajoz) and collaborating centres. The study
was conducted according to the principles expressed in the
declaration of Helsinki.
Genotyping of LINGO1 rs9652490 and rs18856808
polymorphisms
Genomic DNA was obtained from peripheral leukocytes
and purified according to standard procedures. Two
polymorphisms of LINGO1 gene, rs9652490 A/G and
rs11856808 C/T, were genotyped using KASPar assays
according to the manufacturer’s protocol (www.kbioscience.
co.uk). PCR was performed on a 96-well Tetrad 2 Peltier
Thermal Cycler (BIO-RAD, Hercules, CA). PCR KASPar’s
protocol was performed as following: a denaturation
step of 10 min, twenty–eight cycles of 15 sec denaturing
at 94°C, annealing of 20 sec at 57°C, and extension of
30 sec at 72°C. PCR were followed by a final extension
step of 5 min at 72°C. Genotype calling was performed
in an allelic discrimination analysis module of the 7300
CEU ASW JPT
CHB MXL TSI
Figure 1 (See legend on next page.)
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Figure 1 Scheme and linkage analysis of the SNPs analyzed in this study. The linkage figure was composed with Haploview Ver. 3, release
R-2, excluding individuals with > 50% missing genotypes, according to the standard colour scheme (D’/LOD), and the D’ values (×100) are shown
when relevant. Top: The area covers the whole LINGO1 gene as well as the 3’ flanking region. The SNPs tested are marked at the right side of the
figure. These data correspond to Caucasian individuals (Utah residents with ancestry from northern and western Europe). Bottom: Linkage figures
focusing on the two SNPs tested and six SNPs located within the LINGO1 gene. The populations correspond to: CEU, Utah residents with
ancestry from northern and western Europe; ASW, African ancestry in Southwest USA; JPT, Japanese in Tokyo, Japan; CHB, Han Chinese in Beijing,
China; MXL, Mexican ancestry in Los Angeles, California; TSI, Tuscany in Italia. (see the website http://www.sanger.ac.uk/resources/downloads/
human/hapmap3.html).
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Sequence Detection Software v.1.2.3, Applied Biosystems,
Foster City, CA, USA). We sequenced the SNP region in
several individuals for each genotype for quality control of
genotyping. Genotype success rate was 96.8%.
Statistical analysis
Hardy-Weinberg equilibrium (HWE) was analyzed by the
DeFinetti software (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl).
Allelic and genotype frequency analysis was performed
with PLINK v.1.07 software (Shaun Purcell; http://pngu.
mgh.harvard.edu/purcell/plink/). We performed Westfall
and Young’s step-down max (T) permutation procedure
implemented in PLINK v.1.07 by running 100.000 permu-
tations to correct for multiple testing [29]. Level of
statistical significance was considered at corrected
p-values ≤ 0.05. The linkage disequilibrium between the
two polymorphisms was calculated with Haploview Ver. 3.
For categorical variables the intergroup comparison values
were calculated by using the chi-square or Fisher's exact
tests when appropriate. For continuous variables, the
Kolmogorov-Smirnoff test was used to analyze normality
in the distribution. Then, the Student two sample t test
was used for variables that followed a normal distribution
(age and age at onset), and the Mann–Whitney test was
used for the duration of disease and the severity scores
expanded disability status scale and progression index,
because no normal distribution was observed for this par-
ameter.The 95% confidence intervals were also calculated.
The statistical power was calculated for the sample size of
this study (this was determined from allele frequencies
with a genetic model analyzing the frequency for carriers
of the disease gene with OR = 1.5; p = 0.05) [30]. Bilateral
and unilateral associations of the risk with the variantTable 1 Characteristics of the individuals included in the stud
Overall MS patients RR
Gender (females/males) 203/90 11
Age (mean ± SD) 43.9 ± 11.4 40
Age at onset (mean ± SD) 32.8 ± 10.9 29
Disease duration (mean ± SD) 11.1 ± 7.9 10
Expanded disability status scale 4.7 ± 2.2 2.9
Progression index (EDSS/MS duration) 0.5 ± 0.4 0.3allele are as follows rs9652490 G = 80.1% and 87.7% and
rs11856808 T = 91.9% and 96.7%, respectively. Haplotype
reconstruction was performed using the program PHASE
v2.1.1 [31]. We used the default model for recombination
rate variation with 1000 iterations, 500 burn-in iterations
and a thinning interval of 1 as described elsewhere [32].
Results
The frequencies of LINGO1 rs9652490 and rs11856808
genotypes and alleles in patients with MS did not differ
from those of controls (Table 2). The genotype and allele
frequencies in MS patients and healthy subjects were in
Hardy-Weinberg’s equilibrium. Both SNPs were in link-
age disequilibrium with LOD values equal to 48.67 and
36.17 among patients and controls subjects, respectively
(r-squared = 0.46 and 0.48, respectively). Mean age at
onset of MS did not differ significantly between patients
carrying LINGO1 rs9652490 A/A (mean ± SD = 33.0 ±
11.5 years), A/G (mean ± SD = 32.4 ± 9.8 years) and G/G
(mean ± SD = 38.5 ± 24.7 years); (p = 0.818 for the com-
parison of carriers vs. non-carriers of variant alleles), and
between patients with genotypes LINGO1 rs11856808
C/C (mean ± SD = 32.5 ± 11.5 years), C/T (mean ± SD =
32.6 ± 10,6 years) and T/T (mean ± SD = 35.6 ± 10.9
years); (p = 0.835 for the comparison of carriers vs.
non-carriers of variant alleles).
The distribution of rs9652490 and rs11856808 allelic
and genotype frequencies were not influenced by gender
(Table 2). The distribution of the LINGO1 rs9652490
and rs11856808 genotype and allelic frequencies did not
differ between each MS phenotype and controls (Table 3)
or in the severity scores: expanded disability status scale
or progression index. Haplotype analyses indicated that
the commonest rs9652490-rs11856808 haplotype wasy
MS SPMS PPMS Control individuals
5/44 59/32 29/14 221/97
.0 ± 10.5 47.2 ± 9.9 54.4 ± 10.2 43.7 ± 12.4
.5 ± 8.5 34.9 ± 11.8 43.4 ± 11.6 –
.5 ± 8.2 12.3 ± 9.3 11.0 ± 7.7 –
± 1.5 6.0 ± 1.3 6.8 ± 0.9 –
± 0.2 0.6 ± 0.5 0.7 ± 0.4 –
Table 2 LINGO1 genotype and allelic variants of patients with multiple sclerosis (MS) and healthy volunteers
MS PATIENTS
(N = 293, 586
ALLELES)
CONTROLS
(N = 318, 636
ALLELES)
Intergroup
comparison
values
MS WOMEN
(N = 203, 406
ALLELES)
CONTROL WOMEN
(N = 221, 442
ALLELES)
Intergroup
comparison
values
MS MEN
(N = 90, 180
ALLELES)
CONTROL MEN
(N = 97, 194
ALLELES)
Intergroup
comparison
values
rs9652490 GENOTYPE A/A 197 (67.2%) 222 (69.8%) 139 (68.5%) 153 (69.2%) 58 (64.4%) 69 (71.1%)
A/G 92 (31.4%) 86 (27.0%) P = 0.197 62 (30.5%) 60 (27.1%) P = 0.170 30 (33.3%) 26 (26.8%) P = 0.651 *
G/G 4 (1.4%) 10 (3.1%) 2 (1.0%) 8 (3.6%) 2 (2.2%) 2 (2.1%)
Allele A 486 (82.9%) 530 (83.3%) – 340 (83.7%) 366 (82.8%) – 146 (81.1%) 164 (84.5%) –
Allele G 100 (17.1%) 106 (16.7%) OR (95% CI) 66 (16.3%) 76 (17.2%) OR (95% CI) 34 (18.9%) 30 (15.5%) OR (95% CI)
1.03 (0.76-1.39) 0.94 (0.65-1.34) 1.27 (0.74-2.18)
P = 0.853 P = 0.715 P = 0.380
rs11856808 GENOTYPE C/C 137 (46.8%) 145 (45.6%) 95 (46.8%) 101 (45.7%) 42 (46.7%) 44 (45.4%
C/T 126 (43.0%) 149 (46.9%) P = 0.407 90 (44.3%) 103 (46.6%) P = 0.852 36 (40.0%) 46 (47.4%) P = 0.313
T/T 30 (10.2%) 24 (7.5%) 18 (8.9%) 17 (7.7%) 12 (13.3%) 7 (7.2%)
Allele C 400 (68.3%) 439 (69.0%) – 280 (69.0%) 305 (69.0%) – 120 (66.7%) 134 (69.1%) –
Allele T 186 (31.7%) 197 (31.0%) OR (95% CI) 126 (31.0%) 137 (31.0%) OR (95% CI) 60 (33.3%) 60 (30.9%) OR (95% CI)
1.04 (0.81-1.32) 1.00 (0.75-1.34) 1.08 (0.60-1.43)
P = 0.773 P = 0.990 P = 0.725
P values correspond to 3x2 contingency tables (exact test). * Fisher’s exact test.
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Table 3 LINGO1 genotypes and allelic variants in patients with MS, and relation with the evolutive type of MS
RELAPSING-REMITTING
MS (N = 159; 318
ALLELES)
Intergroup
comparison
values
SECONDARY
PROGRESSIVE
MS (N = 91; 182
ALLELES)
Intergroup
comparison
values
PRIMARY
PROGRESSIVE MS
(N = 43; 86 ALLELES)
Intergroup
comparison
values
CONTROLS
(N = 318, 636
ALLELES)
rs9652490
GENOTYPE
A/A 102 (64.2%) 62 (68.1%) 33 (76.7%) 222 (69.8%)
A/G 56 (35.2%) P = 0.055 26 (28.6%) P =0.956 10 (23.3%) P = 0.405 86 (27.0%)
G/G 1 (0.6%) 3 (3.3%) 0 (0.0%) 10 (3.1%)
Allele A 260 (81.8%) – 150 (82.4%) – 76 (88.4%) – 530 (83.3%)
Allele G 58 (18.2%) OR (95% CI) 32 (17.6%) OR (95% CI) 10 (11.6%) OR (95% CI) 106 (16.7%)
1.12 (0.78-1.59) 1.07 (0.69-1.65) 0.66 (0.33-1.31)
P = 0.544 P = 0.771 P = 0.232
rs11856808
GENOTYPE
C/C 67 (42.1%) 43 (47.3%) 27 (62.8%) 145 (45.6%)
C/T 77 (48.4%) P = 0.670 35 (38.5%) P = 0.095 14 (32.6%) P = 0.112 149 (46.9%)
T/T 15 (9.4%) 13 (14.3%) 2 (4.7%) 24 (7.5%)
Allele C 211 (66.4%) – 121 (66.5%) – 68 (79.1%) – 439 (69.0%)
Allele T 107 (33.6%) OR (95% CI) 61 (33.5%) OR (95% CI) 18 (20.9%) OR (95% CI) 197 (31.0%)
1.13 (0.85-1.51) 1.12 (0.79-1.60) 0.59 (0.34-1.02)
P = 0.404 P = 0.515 P = 0.056
P values correspond to 3x2 contingency tables (exact test).
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dividuals), followed by GT (19.4% and 16.6%, respect-
ively) and AT (15.2% and 14.2%, respectively). These
analyses did not reveal any differences in haplotype fre-
quencies on comparing patients and control individuals
(p > 0.05 for all comparisons). Haplotypes did not differ
when subgroups of patients were compared according to
gender, age at onset, MS phenotypes or severity scores
(p > 0.05 for all comparisons).
Discussion
The possible role of LINGO1 in the pathogenesis of MS
makes it reasonable to analyse the possible relationship
between LINGO1 polymorphisms and the risk of MS. In
the present study, we found no significant differences in
allele genotypes, or haplotypes frequencies for the
rs9652490 and rs11856808 polymorphisms when com-
paring patients with MS and healthy control subjects.
Nor were these polymorphisms related with the age at
onset of MS or with the evolutive type of MS. The find-
ings obtained, though negative, are novel and represent
an incremental advance in the knowledge of the clinical
implications of the LINGO1 gene polymorphism.
Some experimental data suggest a possible role of
LINGO1 in the pathogenesis of MS: (a) Nogo-A expres-
sion has been found to be enhanced in surviving
oligodendrocytes, while NgR has been found to be up-regulated in reactive astrocytes and macrophages/micro-
glia in chronic active demyelinating lesions of MS [33], (b)
TROY has been found to be up-regulated, whereas
LINGO1 expression has been found to be reduced, in MS
brains [34], (c) LINGO1 knockout mice have shown earlier
onset of myelination of CNS axons than the wild-type,
and greater resistance to the development of myelin oligo-
dendrocyte glycoprotein (MOG)-induced experimental
autoimmune encephalomyelitis (EAE) [35]; (d) Treatment
with antibody antagonists against LINGO1 function in-
duces functional recovery and increases integrity of axons
in MOG-induced EAE [35], and promotes oligodendro-
cyte precursor cell differentiation and remyelination in
different experimental models of demyelination and
remyelination [36].
The LINGO1 SNPs analyzed in this study have been
studied as putative risk biomarkers for other movement
disorders. A recent meta-analysis, which included 3,972
essential tremor (ET) patients and 20,714 controls for
the LINGO1 rs9652490 polymorphism, and 2,076 ET
patients and 18,792 controls for the rs11856808 poly-
morphism, concluded that the rs11856808 polymorph-
ism was related with increased risk for both total and
familial ET, whereas the rs9652490 polymorphism was
related with increased risk for familial ET [21]. With re-
gard to Parkinson’s disease, another recent meta-
analysis including 5,541 patients and 5,647 controls for
García-Martín et al. BMC Neurology 2013, 13:34 Page 7 of 9
http://www.biomedcentral.com/1471-2377/13/34the rs9652490 polymorphism and 3,276 patients and
3,371 controls for the rs11856808 polymorphism con-
cluded that these polymorphisms could not be consid-
ered as major risk factors for susceptibility to PD [22].
Several SNPs have been described within the LINGO1
gene and in the 3’ flanking region (Figure 1). It is to be
noted that most genetic association studies on LINGO1
focused on the same SNPs which were analyzed in the
present study [17-19,21-24,37-50]. Although several LIN
GO1 nonsynonymous SNPs have been described, namely
rs113329801, rs201732477, rs112205560, rs150289554,
rs113096707, rs188738703, rs200688402, rs200463885,
rs9855, rs201517725, rs184237450, rs77436810, rs1931
00227, rs111741384, rs202233236, rs199976207, rs199
628078, rs201438433, rs140914739, rs200528664, rs111
605415 and rs202223502, none of these SNPs show a
minor allele frequency over 0.0005 (see the website
http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?
showRare=on&chooseRs=all&go=Go&locusId=84894).
Therefore, the identification of one heterozygous indi-
vidual out of 1000 individuals studied is to be expected.
This precluded the analysis of these nonsynonymous
SNPs as putative risk factors. Nevertheless, the two
SNPs studied are linked with other SNPs within the cod-
ing region of the LINGO1 gene. Figure 1 show that link-
age varies depending on the population studied, being
low in individuals of African descent, high in individuals
of Oriental descent or in related populations (of Amerin-
dian descent), and intermediate in individuals of Cauca-
sian descent. The Italian Tuscany population shows a
higher linkage than other Caucasian individuals, prob-
ably due to genetic admixture with other Mediterranean
populations. This admixture took also place in Spain.
The Figure indicates that the two SNPs analyzed in this
study are linked to the rest of the SNPs shown in the
Figure.
The present study has some limitations. First, the size of
analyzed cohorts may not be sufficient for strict conclusions
about LINGO1 role in MS. As was shown in a previous
publication about the role of LINGO1 in essential tremor
risk, individual studies of small number of patients gave
very contradictory results [21]. Second, although the sample
size is adequate to detect an OR as small as 1.5, a more
modest association would not be detected. Third, because
EDSS or progression index are not completely adequate
measures of disease severity, the negative association ob-
served in this study does not rule out a putative association
with disease severity. Moreover, because the cohort study
included MS patients with different degrees of severity, it is
not adequate for the investigation of the influence of
LINGO1 genotypes on the disability or severity of MS (the
ideal study for this purpose should include genotyping of
patients with a recent diagnosis of MS with similar follow-
up periods).Conclusions
In summary, taking in account the limitations of the
present study, our results suggest that rs9652490 and
rs11856808 genotype and allelic variants are not related
with the risk for MS in Caucasian Spanish people.
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